Isoamylamine Binding Detection via Nondenaturing PAGE
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack the ability to directly demonstrate the interaction between gut microbiome metabolites and the transcription machinery of host cells, specifically regarding the regulation of gene expression by bacterial metabolites.
Innovation Solution
The development of a method using nondenaturing polyacrylamide gel electrophoresis (PAGE) to detect the binding site of small molecules, such as isoamylamine (IAA), to target DNA sequences, allowing for the identification of IAA binding to the promoter region of S100A8 and subsequent modulation of gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If nondenaturing polyacrylamide gel electrophoresis (PAGE) is used to detect small molecule binding to DNA, then the ability to directly demonstrate metabolite-DNA interaction is improved, but the complexity of the detection method increases
Solution Approach 1:
The patent uses nondenaturing polyacrylamide gel electrophoresis as an intermediary detection method that separates and visualizes DNA-metabolite complexes based on their migration properties. This intermediary technique enables direct detection of binding without requiring additional labeling or complex assay components, resolving the contradiction by providing a straightforward yet precise detection mechanism.
Solution Approach 2:
The patent replaces more complex molecular biology assays (such as chromatin immunoprecipitation or sequencing) with a simpler electrophoretic separation method. By substituting mechanical/physical separation principles for complex biochemical assays, the method achieves precise detection while reducing overall complexity and requiring fewer specialized reagents.
2Loss of information
If direct binding detection methods are developed to show metabolite interaction with promoter regions, then the understanding of gene regulation mechanisms is improved, but the difficulty of detecting and measuring binding sites increases
Solution Approach 1:
The patent employs ethidium bromide staining, which causes color changes in the gel when DNA-metabolite complexes are present. This visual color change provides direct information about binding site locations, making the detection process more intuitive and easier to interpret while maintaining high measurement accuracy for binding event detection.
3Loss of information
If the role of gut microbiome metabolites in regulating host gene expression is investigated, then the understanding of gut-brain axis mechanisms is improved, but the loss of time in establishing causal relationships increases
Solution Approach 1:
The patent extracts and isolates specific metabolites from the complex gut microbiome (such as isoamylamine) and tests their individual effects on host gene expression. By taking out specific candidates for targeted analysis, the study accelerates the establishment of causal relationships compared to analyzing the entire microbiome mixture, while still providing comprehensive information about gut-brain mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the understanding of how gut microbiome metabolites, like IAA, can directly influence gene expression in host cells, providing insights into the molecular mechanisms linking gut metabolism to brain function and disease processes.
Implementation Method 1
performing nondenaturing polyacrylamide gel electrophoresis (PAGE) on the sample mixture
Implementation Method 2
a shift in the band for the sample mixture relative to a control containing only the DNA oligonucleotide indicates the binding site for the small molecule to the target DNA sequence is present in the DNA oligonucleotide
Data Source
AI summary
Provided are compositions that include an isoamyl alcohol (IAA) sequestration agent, wherein the IAA sequestration agent includes an IAA binding moiety. In some embodiments, the IAA binding moiety is a nucleotide sequence or a peptide or polypeptide (e.g., and antibody or a fragment thereof that includes a paratope) to which IAA binds. In some embodiments, the composition further includes comprising a pharmaceutically acceptable carrier, excipient, or diluent, optionally a pharmaceutically acceptable carrier, excipient, or diluent that is pharmaceutically acceptable for use in a human. The presently disclosed subject matter also provides oligonucleotides, optionally further including a tag, and/or the oligonucleotide includes at least one modified base. Also provided are methods for using the same to reduce and/or delay cognitive decline associated with neurodegenerative disease and/or for sequestering isoamyl alcohol (IAA) produced by microbiota in the gut of subjects.